Metabolic associated liver disease

被引:1
|
作者
Testino, Gianni [1 ,3 ]
Pellicano, Rinaldo [2 ]
机构
[1] Polyclin San Martino Hosp, Alcohol Reg Ctr, Unit Addict & Hepatol, ASL3 C-O, Genoa, Italy
[2] Molinette SGAS Hosp, Unit Gastroenterol, Turin, Italy
[3] Polyclin San martino Hosp, Alcohol Reg Ctr, Unit Addict & Hepatol, ASL3 C-O Padigl 10,Piazzale R Benzi 10, I-16132 Genoa, Italy
关键词
Alcohol drinking; Metabolic syndrome; Non-alcoholic fatty liver disease; Diabetes mellitus; type; 2; NONALCOHOLIC FATTY LIVER; ALCOHOL-USE; HEPATOCELLULAR-CARCINOMA; TRANSIENT ELASTOGRAPHY; BLOOD-PRESSURE; FIBROSIS; RISK; IDENTIFICATION; PERFORMANCE; MANAGEMENT;
D O I
10.23736/S0031-0808.22.04730-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In real practice the patient with liver disease is often the carrier of multiple etiological factors such as metabolic syndrome (MS) and alcohol consumption (AC). Their copresence is often underestimated and AC is not adequately studied. Traditionally to diagnose non-alcoholic fatty liver disease (NAFLD), AC must not exceed 30 gr for men and 20 gr for women per day. This limit should still be reduced, especially in relation to the AC and fibrogenesis ratio and also frequent misestimation of AC or unrecognized MS may underestimate multi caused liver injury. AC is a contributing cause of MS and alcoholic and non-alcoholic liver disease have a substantially overlapping histopathological picture. Moreover, AC and MS are cause and contributing cause of extra-hepatic morbidity and mortality. It can be concluded that the possible simplification of terminology at metabolic associated liver disease (MALD) makes clinical activity more usable and immediate, facilitates better communication and cooperation between scientific societies and specialists who apparently deal with different medical sectors, facilitates early identification of related hepatic and extra-hepatic pathology, allows to "see the person in a unitary way," to create more streamlined care pathways, to reduce the hospitalization rate with relative cost-benefit advantage and to create unitary prevention and health promotion policies.
引用
收藏
页码:555 / 563
页数:9
相关论文
共 50 条
  • [41] Update on genetics and epigenetics in metabolic associated fatty liver disease
    Zhu, Xiaopeng
    Xia, Mingfeng
    Gao, Xin
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2022, 13
  • [42] Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease
    Stefan, Norbert
    Roden, Michael
    DIABETOLOGIE UND STOFFWECHSEL, 2024, 19 : S290 - S296
  • [43] Molecular characterization of metabolic associated fatty liver disease as an immune-mediated inflammatory disease: IMID associated fatty liver disease
    Garcia-Nieto, Enrique
    Carlos Rodriguez-Duque, Juan
    Iruzubieta, Paula
    Garcia-Blanco, Agustin
    Rivas, Coral
    Luisa Cagigal, Maria
    Rueda-Gotor, Javier
    Rivero, Montserrat
    Armesto, Susana
    Antonio Gonzalez-Lopez, Marcos
    Duran-Vian, Carlos
    Esteve Codina, Anna
    Gut, Marta
    Pedro Vaque, Jose
    Crespo, Javier
    Arias Loste, Maria Teresa
    JOURNAL OF HEPATOLOGY, 2022, 77 : S113 - S113
  • [44] Metabolic dysfunction-associated steatotic liver disease and the heart
    Driessen, Stan
    Francque, Sven M.
    Anker, Stefan D.
    Cabezas, Manuel Castro
    Grobbee, Diederick E.
    Tushuizen, Maarten E.
    Holleboom, Adriaan G.
    HEPATOLOGY, 2023,
  • [45] Therapeutic management of metabolic dysfunction associated steatotic liver disease
    Zeng, Jing
    Fan, Jian-Gao
    Francque, Sven M.
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2024, 12 (02) : 177 - 186
  • [46] Postprandial dysfunction in metabolic associated fatty liver disease (MAFLD)
    Grandt, Josephine
    Jensen, Anne Sofie
    Werge, Mikkel
    Rashu, Elias
    Junker, Anders
    Hobolth, Lise
    Mortensen, Christian
    Kristiansen, Maria
    Vyberg, Mogens
    Serizawa, Reza
    Moller, Soren
    Gluud, Lise Lotte
    Albrechtsen, Nicolai J. Wewer
    JOURNAL OF HEPATOLOGY, 2022, 77 : S154 - S154
  • [47] Diabetes and metabolic dysfunction-associated fatty liver disease
    Davis, Timothy M. E.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2021, 123
  • [48] Prevalence and associated metabolic factors of fatty liver disease in the elderly
    Wang, Zhongli
    Xu, Ming
    Peng, Jianhong
    Jiang, Li
    Hu, Zhengguo
    Wang, Hua
    Zhou, Shiqing
    Zhou, Rui
    Hultstrom, Michael
    Lai, En Yin
    EXPERIMENTAL GERONTOLOGY, 2013, 48 (08) : 705 - 709
  • [49] Biomarkers of Metabolic (Dysfunction)-associated Fatty Liver Disease: An Update
    Alharthi, Jawaher
    Eslam, Mohammed
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2022, 10 (01) : 134 - 139
  • [50] Postprandial Dysfunction in Metabolic Associated Fatty Liver Disease (MAFLD)
    Grandt, Josephine
    Jensen, Anne-Sofie H.
    Werge, Mikkel P.
    Rashu, Elias B.
    Junker, Anders
    Hobolth, Lise
    Mortensen, Christian
    Vyberg, Mogens
    Serizawa, Reza
    Moller, Soren
    Gluud, Lise
    Albrechtsen, Nicolai J. Wewer
    DIABETES, 2022, 71